按年龄分层的主动脉瓣狭窄外科主动脉瓣置换术
基于STS成人心脏外科数据库2011年7月至2022年12月的200,849例严重主动脉瓣狭窄行SAVR患者,按年龄(<65岁、65-79岁、≥80岁)及二叶式/三叶式主动脉瓣分层。SAVR年手术量下降45%,≥80岁患者降幅96%;年轻二叶式主动脉瓣患者实际死亡率优于预测死亡率。作者认为SAVR应仍是该人群的首选治疗。
要点
- 研究期间SAVR年手术量从19,560例降至10,851例,降幅45%。
- ≥80岁患者SAVR量从4,914例降至207例,降幅96%。
- 二叶式主动脉瓣相对患病率在<65岁组为49.5%,≥80岁组为4.5%。
核心结论
- 经导管时代SAVR手术量大幅下降,尤其是≥80岁患者和三叶式主动脉瓣患者。
- 年轻二叶式主动脉瓣患者结局优于预期,在主动脉瓣狭窄共享决策中应仔细考虑。
- 作者认为SAVR应仍是该人群的首选治疗。
研究设计与样本
- 基于STS成人心脏外科数据库的队列研究,纳入2011年7月至2022年12月因严重主动脉瓣狭窄行SAVR的成人(≥18岁)患者。
- 共纳入1,238家参与医院的200,849例SAVR患者,其中二叶式主动脉瓣55,326例(27.5%),三叶式主动脉瓣145,526例(72.5%)。
- 按年龄(<65岁、65-79岁、≥80岁)及二叶式/三叶式主动脉瓣状态进行分层比较。
- 主要终点包括手术死亡率、复合并发症与死亡、永久性卒中,并计算基于STS预测死亡风险的观察/预期比值。
主要发现
- 研究期间SAVR年手术量从19,560例降至10,851例,下降45%。
- ≥80岁患者SAVR量从4,914例降至207例,降幅96%,为各年龄组中最大。
- 二叶式主动脉瓣相对患病率:<65岁组为49.5%(69,068例中),65-79岁组为19.1%(104,382例中),≥80岁组为4.5%(27,399例中)。
- 二叶式主动脉瓣患者观察死亡率:<65岁为1.08,65-79岁为1.21,≥80岁为3.68;对应预期死亡率:<65岁为1.22,65-79岁为1.54,≥80岁为3.14,<80岁患者实际死亡率优于预期。
临床怎么用
- 作者认为,在主动脉瓣狭窄的共享决策中应仔细考虑年轻二叶式主动脉瓣患者结局优于预期这一信息。
- 作者认为SAVR应仍是该人群的首选治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The management of aortic stenosis has evolved to stratification by age as reflected in recent societal guidelines. We evaluated age-stratified surgical aortic valve replacement (SAVR) trends and outcomes in patients with bicuspid aortic valve (BAV) or tricuspid aortic valve (TAV) from The Society of Thoracic Surgeons Adult Cardiac Surgery Database. METHODS: This cohort included adults (≥18 years) undergoing SAVR for severe aortic stenosis between July 2011 and December 2022. Comparisons were stratified by age (<65 years, 65-79 years, ≥80 years) and BAV or TAV status. Primary end points included operative mortality, composite morbidity and mortality, and permanent stroke. Observed to expected ratios by The Society of Thoracic Surgeons predicted risk of mortality were calculated. RESULTS: In total, 200,849 SAVR patients (55,326 BAV [27.5%], 145,526 TAV [72.5%]) from 1238 participating hospitals met study criteria. Annual SAVR volumes decreased by 45% (19,560 to 10,851) during the study period. The decrease was greatest (96%) for patients ≥80 years of age (4914 to 207). The relative prevalence of BAV was greater in younger patients (<65 years, 69,068 [49.5% BAV]; 65-79 years, 104,382 [19.1% BAV]; ≥80 years, 27,399 [4.5% BAV]). The observed mortality in <80-year-old BAV patients (<65 years, 1.08; 65-79 years, 1.21; ≥80 years, 3.68) was better than the expected mortality rate (<65 years, 1.22; 65-79 years, 1.54; ≥80 years, 3.14). CONCLUSIONS: SAVR volume in the transcatheter era has decreased substantially, particularly for patients ≥80 years old and for those with TAV. Younger patients with BAV have better than expected outcomes, which should be carefully considered during shared decision-making in the treatment of aortic stenosis. SAVR should remain the preferred therapy in this population.
引用
- Mehta CK, Liu TX, Bonnell L, et al. Age-Stratified Surgical Aortic Valve Replacement for Aortic Stenosis. Ann Thorac Surg. 2024. PMID: 38286202. doi:10.1016/j.athoracsur.2024.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。